A new cell line, designated as Tuwei00, is described. It originated from an Epstein-Barr virus-positive skin tumor biopsy of a heart transplant recipient, whose numerous cutaneous neoplasms were treated with the antiviral drug cidofovir what caused at least transient remissions. The cell line was established in vitro and maintained for more than 70 passages. Cells of early passages were characterized by a slower growth, the inability to form colonies and a higher sensitivity to cidofovir. After overcoming a crisis, the cells grew faster, to a higher density and were able to form adherent colonies from single cells as well as colonies in soft agar. Chromosome analysis showed diploidy/hyperdiploidy at the earlier and hypodiploidy at the later passages. Sensitivity to cidofovir was distinctly higher in early passages of Tuwei00 cells than in later passages and was characterized by distinct decline of cell survival after long term cidofovir exposure. Established normal human keratinocytes, HaCaT cells, which were checked for comparison, showed a low cidofovir sensitivity similar to late passage Tuwei00 cells.

Download full-text PDF

Source

Publication Analysis

Top Keywords

cidofovir sensitivity
8
heart transplant
8
transplant recipient
8
early passages
8
passages characterized
8
sensitivity cidofovir
8
tuwei00 cells
8
cells
6
cidofovir
5
passages
5

Similar Publications

Adenovirus (AdV) infection has been rarely documented in cats and other felids. Partial sequences of the hexon and fiber genes of a Hungarian feline adenovirus isolate (FeAdV isolate) showed a close relationship to human AdV (HAdV) type C1. Further molecular and biological characterization is reported here.

View Article and Find Full Text PDF
Article Synopsis
  • The 2022 mpox outbreak in Belgium involved extensive genomic analysis, revealing 248 complete monkeypox virus genomes related to the MPXV Clade IIb B.1.
  • Researchers identified at least 79 introduction events of the virus into Belgium, but local transmission remained limited.
  • Tecovirimat showed the strongest in vitro effectiveness against the 2022 MPXV strain, indicating its potential as a treatment option.
View Article and Find Full Text PDF
Article Synopsis
  • Human cytomegalovirus (HCMV) is a common virus that mainly affects immunocompromised individuals and newborns, while often being asymptomatic in healthy people; it has a complex genome with high genetic variability.
  • Antiviral treatments for HCMV include several drugs aimed at different viral enzymes, but drug resistance is a significant challenge that can vary in prevalence based on the population and drug used.
  • To effectively manage resistance, there's a need for more sensitive testing methods, alternative treatment strategies, and a push for an effective vaccine against HCMV.
View Article and Find Full Text PDF

Cytomegalovirus (CMV) infection is a common complication in patients undergoing hematopoietic stem cell transplantation (HSCT). Management of refractory CMV infections, especially in developing countries, can be challenging due to the limited availability of second and third-line antiviral drugs or alternative treatments. Here, we present a case of an 8 years-old patient diagnosed with acute myeloid leukemia.

View Article and Find Full Text PDF

A ProTide of AZT Shows Activity Against Human Papillomaviruses.

ChemMedChem

April 2024

Institute of Organic Chemistry, University of Stuttgart, Pfaffenwaldring 55, 70569, Stuttgart, Germany.

Infection by human papillomaviruses (HPV) can cause warts and tumors. So far, no small molecule antiviral has been approved for the treatment of infections with this DNA virus, although preclinical studies show activity for nucleosidic compounds, such as 9-(2-phosphonylmethoxy)ethylguanine (PMEG) or cidofovir. This prompted us to test new prodrug versions of the nucleoside analog 3'-azido-2',3'-dideoxythymidine (AZT), known to be active against reverse transcriptases and approved for the treatment of HIV.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!